Karyopharm Therapeutics | KPTI - Assets


Karyopharm Therapeutics reported $131.42M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Abbott USD 108.25B 968M Sep/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck USD 132.77B 2.97B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Novartis USD 117.15B 1.38B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Takeda JPY 15.27T 391.77B Sep/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Xencor USD 770.5M 45.54M Sep/2026